[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342690-105":59,"doc-detail-342690-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-cytomegalovirus-oncoprotection-across-diverse-populations-tumor-histologies-and-age-groups-the-relevance-for-prospective-vaccinal-therapy-article","Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies, and Age Groups: The Relevance for Prospective Vaccinal Therapy - Article","","The oncogenicity of human cytomegalovirus (CMV) remains under active debate, with growing clinical evidence supporting an anti-cancer effect mediated by CMV-induced T-cell tumor destruction. Existing data often rely on single-center studies and in vitro work, motivating broader geographic validation. The study correlates country-specific CMV seroprevalence across 73 countries with age-standardized incidence of 34 invasive tumors, using IARC/WHO data.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-cytomegalovirus-oncoprotection-across-diverse-populations-tumor-histologies-and-age-groups-the-relevance-for-prospective-vaccinal-therapy-article/342690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-cytomegalovirus-oncoprotection-across-diverse-populations-tumor-histologies-and-age-groups-the-relevance-for-prospective-vaccinal-therapy-article/342690.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about CMV in cancer?","Question",{"text":112,"@type":113},"It examines whether CMV shows an oncoprotective (anti-tumor) relationship rather than purely oncogenic behavior, especially in a global context.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the main data sources and study populations defined?",{"text":117,"@type":113},"Country-specific CMV seroprevalence data across 73 countries were linked to age-standardized incidence rates for 34 invasive tumors, stratified by decadal age periods using IARC/WHO data.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship did the analysis find between CMV seroprevalence and tumor incidence?",{"text":121,"@type":113},"Multivariate linear regression indicated a worldwide inverse correlation between CMV seroprevalence and the incidences of 62.8% of tumors, with additional inverse associations in specific age groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342690,1790269703,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Article  \nHuman Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies, and Age Groups: The Relevance for Prospective Vaccinal Therapy  \nMarko Jankovic 1,2, *, Tara Knezevic 2, Ana Tomic 2, Ognjen Milicevic 2,3, Tanja Jovanovic 4, Irena Djunic 2,5, Biljana Mihaljevic 2,5, Aleksandra Knezevic 1,2 and Milena Todorovic-Balint 2,5  \nCitation: Jankovic, M.; Knezevic, T.; Tomic, A.; Milicevic, O.; Jovanovic, T.; Djunic, I.; Mihaljevic, B.; Knezevic, A.; Todorovic-Balint, M. Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies, and Age Groups:  \nThe Relevance for Prospective Vaccinal Therapy. Int. J. Mol. Sci. 2024, 25, 3741. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25073741  \nAcademic Editor: Luca Roncati  \nReceived: 31 January 2024  \nRevised: 18 March 2024  \nAccepted: 22 March 2024  \nPublished: 27 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Virology, Institute of Microbiology and Immunology, 1 Dr Subotica Street,  \n11000 Belgrade, Serbia; [aleksandra.knezevic@med.bg.ac.rs](aleksandra.knezevic@med.bg.ac.rs)  \n2 Faculty of Medicine, University of Belgrade, 8 Dr Subotica Street, 11000 Belgrade, Serbia; [tara.knezevic@gmail.com](tara.knezevic@gmail.com) (T.K.); [anatomic9977@gmail.com](anatomic9977@gmail.com) (A.T.); [ognjen011@gmail.com](ognjen011@gmail.com) (O.M.); [irenadjunic04@gmail.com](irenadjunic04@gmail.com) (I.D.); [bilja.mihaljevic@gmail.com](bilja.mihaljevic@gmail.com) (B.M.); [bb.lena@gmail.com](bb.lena@gmail.com) (M.T.-B.)  \n3 Institute of Medical Statistics and Informatics, 15 Dr Subotica Street, 11000 Belgrade, Serbia  \n4 Institute for Biocides and Medical Ecology, 16 Trebevicka Street, 11000 Belgrade, Serbia; [tanja.jovanovic@biocidi.org.rs](tanja.jovanovic@biocidi.org.rs)  \n5 Clinic of Hematology, University Clinical Centre of Serbia, 2 Dr Koste Todorovica Street,  \n11000 Belgrade, Serbia  \n* [Correspondence: marko.jankovic@med.bg.ac.rs](Correspondence: marko.jankovic@med.bg.ac.rs)  \nAbstract: The oncogenicity of the human cytomegalovirus (CMV) is currently being widely debated. Most recently, mounting clinical evidence suggests an anti-cancer effect via CMV-induced T cellmediated tumor destruction. However, the data were mostly obtained from single-center studies and in vitro experiments. Broad geographic coverage is required to offer a global perspective. Our study examined the correlation between country-specific CMV seroprevalence (across 73 countries) and the age-standardized incidence rate (of 34 invasive tumors) . The populations studied were stratified according to decadal age periods as the immunologic effects of CMV seropositivity may depend upon age at initial infection. The International Agency for Research on Cancer of the World Health Organization (IARC WHO) database was used. The multivariate linear regression analysis revealed a worldwide inverse correlation between CMV seroprevalence and the incidences of 62.8% tumors. Notably, this inverse link persists for all cancers combined (Spearman’s ρ = −0.732, p \u003C 0.001;β = −0.482, p \u003C 0 .001, adjusted R2 = 0 .737) . An antithetical and significant correlation was also observed in particular age groups for the vast majority of tumors. Our results corroborate the conclusions of previous studies and indicate that this oncopreventive phenomenon holds true on a global scale. It applies to a wide spectrum of cancer histologies, additionally supporting the idea of a common underlying mechanism—CMV-stimulated T cell tumor targeting. Although these results further advance the notion of CMV-based therapies, in-depth investigation of ho","cbCaiu2qTMMTZCJf","https://ap.wps.com/l/cbCaiu2qTMMTZCJf","pdf",1064700,"English","# Abstract\n# Introduction","[{\"question\":\"What question does the study address about CMV in cancer?\",\"answer\":\"It examines whether CMV shows an oncoprotective (anti-tumor) relationship rather than purely oncogenic behavior, especially in a global context.\"},{\"question\":\"How were the main data sources and study populations defined?\",\"answer\":\"Country-specific CMV seroprevalence data across 73 countries were linked to age-standardized incidence rates for 34 invasive tumors, stratified by decadal age periods using IARC/WHO data.\"},{\"question\":\"What relationship did the analysis find between CMV seroprevalence and tumor incidence?\",\"answer\":\"Multivariate linear regression indicated a worldwide inverse correlation between CMV seroprevalence and the incidences of 62.8% of tumors, with additional inverse associations in specific age groups.\"}]","Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies, and Age Groups: The Relevance for Prospective Vaccinal Therapy - Article | PDF",1790047728,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbdbb6795751cb6c08e79c230c070220.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1460d4215eac0895bdb872b426de92d4.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/899a437e53ab7b8b5aaf8b6d53575743.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a24e85aeb21a403e826e8aa87df13456.webp",980,1385]